AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CLNN · NASDAQ · Biotechnology

Clene

Develops CNM-Au8, an investigational oral therapy for ALS and multiple sclerosis.

$4.23

After-hours close−0.05 (−1.17%)

At close$4.28(−4.25%)

Something off on this page? Send us feedback.

Profile

Clene Inc.CLNNHealth Care

CNM-Au8 is its principal drug candidate, an oral gold-nanocrystal therapy being developed for ALS and multiple sclerosis. The clinical-stage company has no commercial drug-candidate sales and depends on clinical, regulatory, financing, and third-party execution.

Built around clean-surfaced nanocrystal therapeutics, the pipeline centers on CNM-Au8, an investigational oral gold-nanocrystal therapy. The company is developing it to address mitochondrial function, the NAD pathway, and oxidative stress in neurodegenerative diseases, including ALS and multiple sclerosis.

Research, development, and manufacturing are split between Salt Lake City and North East, Maryland, with clinical work supported by CROs and research collaborators. CNM-Au8 receives substantially all research and development spending, while no commercial drug-candidate sales have been reported.

Progress depends on clinical and regulatory execution, capital for development and commercialization, third-party CRO and vendor performance, intellectual-property protection, and retention of key people. The business remains development-stage, with limited operating history and no material drug-product revenue.

Company facts

CEORob Etherington

ListedDec 31, 2020

ExchangeNASDAQ

HeadquartersSalt Lake City, UT

CountryUnited States

Employees79

CIK0001822791

ISINUS1856342019

Key statistics

Market cap$54.1M

EPS (ttm)−$3.55

P/E (ttm)−1.19

ROE215.0%

P/B−2.11

P/S274.38

Dividend yield—

Beta1.86vs XLV 0.30

Year to date −25.8% · Average volume (30d) 74.8K

Analysts

Price target, next 12 months$50.00+1,082.0%Median of 8 analysts · vs the Aug 28 close

ConsensusBuy7 of 8 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $4.23

High$50.00+1,082.0%

Median$50.00+1,082.0%

Low$50.00+1,082.0%

12 months agoNowIn 12 months

Latest analyst notes

No analyst notes in the last 24 months.

Earnings

EPS

Estimate−$0.46

ReportedDue Nov 12, 2026

Revenue

Estimate$70.0K

ReportedDue Nov 12, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 14, 2026Q2 FY26	−$0.37	−$1.08	−193.5%	$61.0K	$90.0K	+47.5%	−1.19%
May 14, 2026Q1 FY26	−$0.50	−$0.31	+38.0%	$50.8K	$15.0K	−70.4%	+1.28%
Mar 12, 2026Q4 FY25	−$0.74	−$0.88	−18.9%	$26.0K	$77.0K	+196.2%	−3.38%
Nov 13, 2025Q3 FY25	−$0.60	−$0.85	−41.7%	$64.3K	$15.0K	−76.7%	+16.71%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$81.0K	$27.0K	$15.0K	$77.0K	$15.0K	$90.0K
Gross profit	$61.0K	$27.0K	$15.0K	$54.0K	−$340.0K	$54.0K
Operating income	−$4.1M	−$5.9M	−$5.6M	−$7.2M	−$2.1M	−$5.3M
Net income	−$751.0K	−$7.4M	−$8.8M	−$9.2M	−$8.1M	−$13.4M
Diluted EPS	−$0.09	−$0.78	−$0.85	−$0.93	−$0.69	−$1.08
Gross margin	75.3%	100.0%	100.0%	70.1%	-2,266.7%	60.0%
Operating margin	-5,032.1%	-21,718.5%	-37,653.3%	-9,407.8%	-13,740.0%	-5,941.1%

Fiscal years (4-quarter sums)FY21 $723.0K · FY22 $473.0K · FY23 $654.0K · FY24 $342.0K · FY25 $200.0K

Revenue by product · Q2 FY26

Product$74.0K · 82%

Royalty$16.0K · 18%

Balance sheet, Jun 30, 2026Cash & short-term investments $9.7M · Total debt $22.3M · Total assets $23.0M · Shareholders' equity −$24.8M

Dividends

No dividends on record.

Ownership

Institutions 17.17%2.19M sharesInsiders 5.95%759.9K sharesOther 76.88%9.82M shares

Shares outstanding 12.78M · Float 9.59M · 75.0% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Vivo Opportunity Fund Holdings, L.P.	1.89M	9.99%	13G	May 12, 2026
Alison Mosca	1.83M	13.00%	13G	May 14, 2026
Ugwumba Chidozie	1.35M	9.70%	13G	May 15, 2026
Empery Asset Management, LP	916.5K	7.17%	13G	Aug 4, 2026
General Resonance LLC · 10 percent owner	704.6K	5.51%	Form 4	Aug 21, 2025

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
May 12, 2026	Chidozie Ugwumba	10 percent owner	−73,296	$6.20
May 11, 2026	Chidozie Ugwumba	10 percent owner	−22,177	$6.75
May 4, 2026	Chidozie Ugwumba	10 percent owner	−72,884	$6.80
May 1, 2026	Chidozie Ugwumba	10 percent owner	−5,795	$6.01
Apr 30, 2026	Chidozie Ugwumba	10 percent owner	−5,736	$6.08